slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 5,851-5,880
Pages 350
Rows per page 30
Slide type
5,851-5,880 of 10,471
13
The slide highlights regulatory milestones as a proxy for product validation and market readiness.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
16
The 2023 figure is marked with an asterisk indicating revenue guidance.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
17
The chart shows a progression from negative margin to positive margin.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a bar chart to demonstrate financial discipline and outlines three key areas of investment.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
11
The chart demonstrates the efficacy of NXC-201 (formerly HBI0101) in clearing diseased cells.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
17
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
25
The chart uses a grouped bar structure to compare efficacy across patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
27
The slide uses a two-column layout to compare clinical data for two different indications, supported by competitor market data.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
28
The chart illustrates deepening responses over time in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
36
Slide contains three distinct data visualizations comparing IMX-110 against standard of care or historical benchmarks.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
37
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in turning cold tumors hot.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
38
Includes survival curves, median survival comparison, and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
40
Includes waterfall chart for best percentage change and line charts for longitudinal tumor size tracking against PD/PR thresholds.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
42
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
48
Includes two sets of charts: tumor volume line graphs and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
13
The slide presents clinical trial data (STAI-G scores) over 24 weeks, highlighting significant symptom reduction and safety profile.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Traction1 hit
24
The chart shows improvement in social anxiety at 1 month and 6 months, indicating durability of effect.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
06
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
07
The slide uses a 'Target vs Status' framework to demonstrate progress.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
09
The slide presents two line charts: one comparing BGM vs Invasive CGM, and one showing raw sugarBEAT data.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
10
Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
11
The table displays statistical significance (p-values) for multiple clinical endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
12
TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
18
The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
32
The slide uses two line charts to visualize clinical trial data with p-values and delta LSM values.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
14
The slide uses a grid of metrics to present financial performance.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · FinancialsLoop · Golden Circle1 hit
10
Includes a legend for extraordinary items and a disclaimer regarding non-GAAP adjustments for FY 2022.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
12
The slide uses a Venn-like circular layout to present two key capital return metrics alongside qualitative operational targets.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
13
The slide uses a grid of 8 metric cards, each with an icon, a headline number, and a descriptive sub-text.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit
16
The chart highlights the acquisition of Crestmark in 2018.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit